GlassScriptPhysician profile
Sarah R Levy
NPI 1790846764
$3,245.93
in general payments reported to CMS, 2019-2025
29 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,174 · 2022: $581 · 2023: $766 · 2024: $428 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $865.03 | 2021-2025 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $459.83 | 2021-2024 | Relistor |
| Abbvie INC. | $340.45 | 2021-2023 | |
| Orexo US, INC. | $187.62 | 2021-2025 | Zubsolv |
| Almatica Pharma LLC | $175.93 | 2021-2023 | Gralise |
| Scilex Pharmaceuticals INC. | $155.32 | 2021-2024 | Ztlido |
| Redhill Biopharma INC. | $144.49 | 2021 | |
| Virtus Pharmaceuticals LLC | $83.37 | 2021 | |
| Upsher-Smith Laboratories LLC | $76.53 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $74.40 | 2021 | |
| Uswm, LLC | $65.17 | 2022-2023 | Lucemyra, Zimhi |
| Amgen INC. | $65.12 | 2021 | |
| Abbott Laboratories | $55.99 | 2024-2025 | Ensite |
| Horizon Therapeutics Plc | $55.02 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $53.45 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.72 | 2021-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $43.39 | 2023-2024 | Quviviq |
| Eisai INC. | $35.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.73 | 2021 | |
| Valinor Pharma, LLC | $34.43 | 2025 | Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $25.99 | 2021 | |
| Braeburn INC. | $25.83 | 2025 | Brixadi |
| Forte Bio-Pharma LLC | $24.02 | 2021 | |
| Impel Pharmaceuticals INC. | $23.83 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $23.64 | 2025 | |
| Lundbeck LLC | $21.16 | 2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $21.11 | 2021 | |
| Lilly USA, LLC | $16.28 | 2022 | |
| Currax Pharmaceuticals LLC | $12.76 | 2023 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.